Practical Pathological Assessment of Residual Cancer Burden (RCB) After Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Invasive Breast Carcinoma: A Case Report.
- 1Department of Pathology and Laboratory Medicine, All India Institute of Medical Sciences, Bibinagar, Bibinagar, IND.
- 2Department of Radiation Oncology, All India Institute of Medical Sciences, Bibinagar, Bibinagar, IND.
Abstract
Neoadjuvant therapy is routinely used in human epidermal growth factor receptor 2 (HER2)-positive breast carcinoma and permits the assessment of treatment response in the surgical specimen. Although pathological complete response (pCR) is an important endpoint, it is binary and does not quantify the extent of residual disease in patients with non-pCR. The Residual Cancer Burden (RCB) index provides a standardized quantitative assessment incorporating the dimensions of the treated tumor bed, residual cancer cellularity, in situ component, and nodal involvement. We report a 48-year-old woman with HER2-positive, estrogen receptor/progesterone receptor (ER/PR)-negative invasive breast carcinoma who received six cycles of neoadjuvant TCH (docetaxel, carboplatin, and trastuzumab) followed by modified radical mastectomy. Gross examination showed no residual mass but identified a fibrotic tumor bed measuring 7 × 5 × 5 cm. Microscopy demonstrated a single residual invasive focus measuring 0.4 × 0.4 cm with 10% overall cancer cellularity, 1% in situ component, and no metastatic tumor in 13 axillary lymph nodes. The RCB index was 1.891 (RCB-II), with final staging of ypT1aN0, and adjuvant ado-trastuzumab emtansine (T-DM1) was initiated. This case is not novel in RCB or HER2-directed therapy, but it demonstrates the importance of meticulous tumor-bed evaluation after neoadjuvant chemotherapy. Treatment-related fibrosis and inflammatory change may obscure scattered residual carcinoma, and a small residual invasive focus may coexist with a substantially larger treated tumor bed. Accurate RCB assessment therefore requires correlation of gross findings, microscopy, nodal evaluation, and pre-treatment disease location. In this setting, RCB complements pCR by providing a reproducible description of residual disease that can support multidisciplinary risk assessment and management.
Related
- Comparative effectiveness of neoadjuvant treatment strategies and predictors of pathological complete response in locally advanced esophageal squamous cell carcinoma: a real-world retrospective cohort study
- Clinical and CT body-composition model for major pathological response to neoadjuvant tislelizumab, albumin-bound paclitaxel, and nedaplatin in esophageal squamous cell carcinoma
- Assessment of shear wave elastography for evaluating neoadjuvant chemotherapy efficacy in breast cancer: correlation of stiffness changes with pathological response
- Relative change rate of neutrophil-to-albumin ratio (ΔNAR) during neoadjuvant chemotherapy predicts axillary pathological complete response in locally advanced breast cancer
- Real-world outcomes of neoadjuvant targeted therapy in resectable epidermal growth factor receptor mutation-positive non-small cell lung cancer: a retrospective study.
BibTeX
@article{rathod2026practical,
title = {{Practical Pathological Assessment of Residual Cancer Burden (RCB) After Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Invasive Breast Carcinoma: A Case Report.}},
author = {Gunvanti Rathod and Chandramouli R and Immanuel Pradeep and Ajay Kumar Kondeti},
journal = {Cureus},
year = {2026},
month = oct,
doi = {10.7759/cureus.117596},
url = {https://europepmc.org/article/MED/42997876},
note = {CC BY},
}
RIS
TY - JOUR
TI - Practical Pathological Assessment of Residual Cancer Burden (RCB) After Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Invasive Breast Carcinoma: A Case Report.
AU - Gunvanti Rathod
AU - Chandramouli R
AU - Immanuel Pradeep
AU - Ajay Kumar Kondeti
PY - 2026
DA - 2026/10/07
JO - Cureus
DO - 10.7759/cureus.117596
UR - https://europepmc.org/article/MED/42997876
AB - Neoadjuvant therapy is routinely used in human epidermal growth factor receptor 2 (HER2)-positive breast carcinoma and permits the assessment of treatment response in the surgical specimen. Although pathological complete response (pCR) is an important endpoint, it is binary and does not quantify the extent of residual disease in patients with non-pCR. The Residual Cancer Burden (RCB) index provides a standardized quantitative assessment incorporating the dimensions of the treated tumor bed, residual cancer cellularity, in situ component, and nodal involvement. We report a 48-year-old woman with HER2-positive, estrogen receptor/progesterone receptor (ER/PR)-negative invasive breast carcinoma who received six cycles of neoadjuvant TCH (docetaxel, carboplatin, and trastuzumab) followed by modified radical mastectomy. Gross examination showed no residual mass but identified a fibrotic tumor bed measuring 7 × 5 × 5 cm. Microscopy demonstrated a single residual invasive focus measuring 0.4 × 0.4 cm with 10% overall cancer cellularity, 1% in situ component, and no metastatic tumor in 13 axillary lymph nodes. The RCB index was 1.891 (RCB-II), with final staging of ypT1aN0, and adjuvant ado-trastuzumab emtansine (T-DM1) was initiated. This case is not novel in RCB or HER2-directed therapy, but it demonstrates the importance of meticulous tumor-bed evaluation after neoadjuvant chemotherapy. Treatment-related fibrosis and inflammatory change may obscure scattered residual carcinoma, and a small residual invasive focus may coexist with a substantially larger treated tumor bed. Accurate RCB assessment therefore requires correlation of gross findings, microscopy, nodal evaluation, and pre-treatment disease location. In this setting, RCB complements pCR by providing a reproducible description of residual disease that can support multidisciplinary risk assessment and management.
SN - 2168-8184
ER -